abstract |
The present invention is directed to the field of treating conditions related to biliary cholesterol crystallization, particularly to the administration of inhibitors of Stearoyl Coenzyme A Desaturase 1, wherein the inhibitor of SCD1 enzymatic activity is not a fatty acid bile acid conjugate (FABAC). |